InflaRx N : 11-2023-InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update -November 01, 2023 at 09:13 am EDT

Jena, Germany, November 1, 2023 - InflaRx N.V. , a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results...

Related Keywords

United States ,Germany ,German ,Thomas Taapken ,German Ministry Of Education ,Development Expenses ,Development Of Vilobelimab ,Drug Administration ,European Medicines Agency ,Inflarx Stops Development Of Vilobelimab ,European Union ,German Ministry Of Health ,Recent Highlights ,Business Update ,Topline Results ,Single Ascending Dose ,Phasei Trial Support Best In Class Potential ,Pyoderma Gangrenosum ,Authorization Application ,Critically Ill ,European Committee ,Medicinal Products ,Human Use ,Emergency Use Authorization ,Cutaneous Squamous Cell Carcinoma ,German Ministry ,Chief Financial Officer ,Marketing Expenses ,Administrative Expenses ,Cash Used ,Markets ,